SNF202213 - Patient Card 165mm(H) x 90mm(W)

INSIDE

90mm(W)

55mm(H)



65mm(H

90mm(W)

WARNING FOR HEALTHCARE PROVIDERS



Please note this patient is receiving treatment with SARCLISA (isatuximab).



This patient card contains important safety information that you need to be aware of before, during, and after treatment with isatuximab.



Treatment with isatuximab binds to CD38 on red blood cells (RBCs) and is associated with a Risk of Interference with blood typing (positive indirect Coombs Test), which may persist for approximately 6 months after the last isatuximab infusion.




To avoid potential problems with RBC transfusion, you should perform blood type and screen tests prior to the first infusion of isatuximab. Phenotyping may be considered as per local practice.



If treatment with isatuximab has already started and in the event of a planned transfusion, you should notify the blood bank that the patient is receiving isatuximab and its risk of Interference with Indirect Antiglobulin Tests.





ΝΟΙΤΑΜЯΟΊΝΙ ΥΜ 🌄





PATIENT CARD

DEAR PATIENT RECEIVING SARCLISA (ISATUXIMAB)



Provide this card to healthcare providers before blood transfusion.



Keep this card with you at all times and until 6 months after the last dose of isatuximab.




If you notice any side effects, talk to your doctor or pharmacist.



Please complete this section or ask your doctor to do it.





The result of my indirect antiglobulin test (indirect Coombs test) was:

Negative

Positive for the following antibodies:

MY DOCTOR'S INFORMATION

In case of emergency, or if you find this card, please contact my doctor using the details below.

Doctor's Name:

Doctor's Phone:

Patient Card: Version 17 JAN 2025

This document has been approved by HSA as of 17-10-2022 MAT-SG-2500018

sanofi